HEALTHJun 8 · 14:30 UTCCNBC TOP

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly are competing in the GLP-1 pill market as they prepare to target seniors with Medicare coverage. The two companies have extended their rivalry to this new area of pharmaceutical development.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Novo NordiskorganizationEli LillyorganizationGLP-1 pillstopicMedicareorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 7 · 23:35 UTC
The Wegovy pill is still dominating the GLP-1 pill market
BUSINESSApr 16 · 05:46 UTC
Sun Pharma, Grünenthal Are Said to Vie for US-Listed Organon
BUSINESSMay 11 · 20:28 UTC
Hims Sales Miss on Rising Competition for Weight-Loss Drugs
BUSINESSApr 14 · 15:02 UTC
Novo Nordisk partners with OpenAI in weight loss drug race
BUSINESSMay 6 · 06:18 UTC
Novo Raises Forecast as Wegovy Pill Fuels Sales
BUSINESSMay 6 · 20:01 UTC
Only one of Berkshire Hathaway and SoftBank can survive